Skip to main content

FDA clears heart monitor for coronavirus patients using hydroxychloroquine

The Food and Drug Administration (FDA) today granted Emergency Use Authorization for a wearable biosensor called the VitalPatch, which can be used to monitor the heart rhythms of patients who have been treated for coronavirus with hydroxychloroquine.

The wearable patch adheres to a patient’s skin just above their heart and can be worn for seven days. It monitors for 22 different types of arrhythmia and fibrillation, as well as 11 other physiological signs, many of which coincide with symptoms of COVID-19, the disease caused by the virus, said Peter Van Haur, CEO of VitalConnect, maker of the sensor.

Recommended Videos
Coronavirus is wreaking havoc on the world, and will continue to for months to come — but what exactly are we doing to fight it? Have we made any progress on a vaccine? Here’s what you need to know
coronavirus taiwan asia technology success science researcher getty

The data is then streamed to a tablet that the patient and their health care team can monitor for any irregularities. The patient can then remain sequestered at home.

The drug hydroxychloroquine is commonly used to treat malaria, and has some dangerous side effects including what’s called “QT interval prolongation,” as well as life-threatening “arrhythmias.” Essentially, the drug can make your heart start beating irregularly and very quickly, which can lead to fainting spells, seizures, and even death.

In its letter of authorization, the FDA said that there are now “public health needs for vital sign and ECG monitoring for complications related to COVID-19 or its treatment,” since the “proposed treatments for COVID-19 include the use of drugs that can prolong QT intervals and may cause life-threatening arrhythmias.”

Based on this, the FDA has announced that VitalPatch “may be effective” for remote heart monitoring for patients that have undergone treatment for COVID-19 using drugs that can affect their heart.

“When COVID 19 hit, there was a large need for a few different things. One was to quarantine COVID patients, but also to still be able to monitor them in a remote fashion,” Haur told Digital Trends.

VitalConnect launched its patch around a year and a half ago, Van Haur said, and has about 100,000 patches on the market, including in nursing homes and assisted care facilities, as well as pharmaceutical companies that are running trials on new drugs.

For several weeks, President Donald Trump has pushed hydroxychloroquine as a possible treatment for COVID-19.

Studies have been inconclusive about the effectiveness of the drug, but some doctors have begun using it to treat coronavirus symptoms. The FDA recently advised people not to treat themselves with the drug without a doctor’s supervision.

Maya Shwayder
I'm a multimedia journalist currently based in New England. I previously worked for DW News/Deutsche Welle as an anchor and…
Google just gave vision to AI, but it’s still not available for everyone
Gemini Live App on the Galaxy S25 Ultra broadcast to a TV showing the Gemini app with the camera feature open

Google has just officially announced the roll out of a powerful Gemini AI feature that means the intelligence can now see.

This started in March as Google began to show off Gemini Live, but it's now become more widely available.

Read more
This modular Pebble and Apple Watch underdog just smashed funding goals
UNA Watch

Both the Pebble Watch and Apple Watch are due some fierce competition as a new modular brand, UNA, is gaining some serous backing and excitement.

The UNA Watch is the creation of a Scottish company that wants to give everyone modular control of smartwatch upgrades and repairs.

Read more
Tesla, Warner Bros. dodge some claims in ‘Blade Runner 2049’ lawsuit, copyright battle continues
Tesla Cybercab at night

Tesla and Warner Bros. scored a partial legal victory as a federal judge dismissed several claims in a lawsuit filed by Alcon Entertainment, a production company behind the 2017 sci-fi movie Blade Runner 2049, Reuters reports.
The lawsuit accused the two companies of using imagery from the film to promote Tesla’s autonomous Cybercab vehicle at an event hosted by Tesla CEO Elon Musk at Warner Bros. Discovery (WBD) Studios in Hollywood in October of last year.
U.S. District Judge George Wu indicated he was inclined to dismiss Alcon’s allegations that Tesla and Warner Bros. violated trademark law, according to Reuters. Specifically, the judge said Musk only referenced the original Blade Runner movie at the event, and noted that Tesla and Alcon are not competitors.
"Tesla and Musk are looking to sell cars," Reuters quoted Wu as saying. "Plaintiff is plainly not in that line of business."
Wu also dismissed most of Alcon's claims against Warner Bros., the distributor of the Blade Runner franchise.
However, the judge allowed Alcon to continue its copyright infringement claims against Tesla for its alleged use of AI-generated images mimicking scenes from Blade Runner 2049 without permission.
Alcan says that just hours before the Cybercab event, it had turned down a request from Tesla and WBD to use “an icononic still image” from the movie.
In the lawsuit, Alcon explained its decision by saying that “any prudent brand considering any Tesla partnership has to take Musk’s massively amplified, highly politicized, capricious and arbitrary behavior, which sometimes veers into hate speech, into account.”
Alcon further said it did not want Blade Runner 2049 “to be affiliated with Musk, Tesla, or any Musk company, for all of these reasons.”
But according to Alcon, Tesla went ahead with feeding images from Blade Runner 2049 into an AI image generator to yield a still image that appeared on screen for 10 seconds during the Cybercab event. With the image featured in the background, Musk directly referenced Blade Runner.
Alcon also said that Musk’s reference to Blade Runner 2049 was not a coincidence as the movie features a “strikingly designed, artificially intelligent, fully autonomous car.”

Read more